Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Melody Heeju Hong, 17, is the first student from General Douglas MacArthur High School in the Levittown school district to be ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

This was the stock's second consecutive day of losses.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 3.58% to $718.16 Tuesday, on what proved to be an all-around grim trading ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $134,486.89 today based ...

Matteo Paz built a machine-learning algorithm in high school to analyze heaps of data for NASA. He just won a $250,000 ...

At the CIO 100 Symposium and Awards, Lee Rennick, executive director of CIO Communities for CIO.com, sat with Bob McCowan, SVP and CIO at Regeneron Pharmaceuticals, and discussed their award-winning ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...